cyrilzakka/clinical-trials huggingface dataset:
Markers of Neurological Damage Post Covid-19 in PLWH

Both HIV infection and Covid-19 are associated to cognitive and psychiatric impairment, like anxiety and depression. These disturbs are well-known in HIV infection and partially characterized in Covid-19.

HIV has an high neurotropism and the HIV-associated dementia was one of the most frequent clinical complications and principal cause of death before the introduction of antiretroviral theraphy (ART). However, also in PLWH taking ART and with suppressed viral load over years, the proportion of neuro-cognitive impairment, anxiety and depression remain higher then the general population.

These problems may be the consequence of a persistent systemic and central nervous system (CNS) immuno-activation caused by the persistence of viral reservoir in the peripheric and tissutal lymphocytes.

Neurological and psychiatric problems have been described in a variable proportion in patients with corona virus disease 19 (COVID-19) and in the complex it doesn't seems to be the direct consequence of CNS cellular infection, but rather of inflammation and coagulations disorder due to COVID-19 in the nervous tissue.

Eligibility Criteria:
Inclusion Criteria:

* HIV+ COVID+: people living with HIV that get corona virus disease 19 (COVID19) diagnosed at least 9 month ago with a positive rino-pharyngeal swab (molecular or antigenic), or with compatible clinic and a positive serologic test for Sars-CoV2 before the vaccination; Age \> 50 years old, no gender.
* HIV+ COVID-: people living with HIV that had not get COVID19. Age\>50 years; no gender.
* HIV- COVID+: people without HIV that get COVID19 diagnosed at least 9 month ago with a positive rino-pharyngeal swab (molecular or antigenic), or with compatible clinic and a positive serologic test for Sars-CoV2 before the vaccination; Age \> 50 years old, no gender.
* HIV- COVID-: people without HIV that had not get COVID19 (healthy people and volunteers) Age\>50 years; no gender.

Exclusion Criteria:

* Inability to perform the neuro-cognitive or functional tests due to neurologic deficit (inability to writing, reading, understand how to perform the tests)
Popliteal Plexus Block for Postoperative Pain After ACL Reconstruction

The study aims to investigate the effect of the popliteal plexus block (PPB) on postoperative pain in patients undergoing anterior cruciate ligament (ACL) reconstruction.

Postoperative pain following ACL reconstruction can be alleviated with an ultrasound-guided femoral triangle block (FTB). However, it is the investigators' observation that 10-20 % of the patients still complain of intense pain localized in the center of the knee.

Cadaver dissection studies have shown that an injection into the distal part of the adductor canal will spread to the popliteal fossa, and one dissection study showed consistent spread to the popliteal plexus.

The study team hypothesized that a PPB will reduce the postoperative pain, when it is used as a supplement to the FTB in patients undergoing ACL reconstruction.

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing ACL reconstruction on one of the two trial sites
* Age ≥ 18
* American Society of Anesthesiologists (ASA) status I-III
* Informed consent

Exclusion Criteria:

* Patients unable to cooperate
* Patients not able to speak Danish or with other communication problems
* Pregnancy
* Contraindication towards any medical product used in the study
* Preoperatively reduced sensation on the medial and lateral part of the lower leg
* Patients with diabetes requiring medical treatment
* Preoperative intake of opioids (dosed \> once daily)
* ACL revision
A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH

AK102 is being developed for the treatment of HoFH. The study will be conducted in 2 parts, part 1 is open label, single arm study to evaluate the safety, tolerability and efficacy of PCSK9 inhibitor AK102, and part 2 is double blind, randomized, placebo controlled study to evaluate the efficacy and safety of PCSK9 inhibitor AK102. The treatment period will last 12 week.


Eligibility Criteria:
Inclusion Criteria:

* Males and females, ≥18 years of age with a diagnosis of homozygous familial hypercholesterolemia by genetic confirmation or a clinical diagnosis based on a history of an untreated low-density lipoprotein cholesterol (LDL-C) concentration \>500 mg/deciliter (dL) \[13 millimoles/liter (mmol/L)\] together with either xanthoma before 10 years of age or evidence of heterozygous familial hypercholesterolemia in both parents
* Stable on pre-existing, lipid-lowering therapies (statins in combination with ezetimibe) for at least 4 weeks with no planned medication or dose change for the duration of study participation
* Fasting central lab LDL-C concentration \>130 mg/dL (3.4 mmol/L) and triglyceride concentration \<400 mg/dL (4.5 mmol/L).
* Body weight of 40 kilograms (kg) or greater at screening

Exclusion Criteria:

* Received LDL plasma replacement therapy within 8 weeks before Investigational product administration
* Received Lomitapide or Mipomersen within 5 months before Investigational product administration
* Received prior treatment with PCSK9 inhibitors or AK102.
* Unexplained creatine kinase (CK) ≥ 5 times the upper limit of normal (ULN)
* Subjects with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) DNA exceeding 500 IU/ mL or active hepatitis C virus (HCV) should be excluded. Subjects with non-active HBsAg carriers, treated and stable hepatitis B (HBV DNA \<500 IU/ mL) , and cured hepatitis C can be enrolled. Subjects with positive HCV antibodies are eligible only if the HCV RNA test results are negative.
* Known allergic reactions to any ingredients of AK102
* Any other condition(s) that would compromise the safety of the patient or compromise the quality of the clinical study as judged by the Investigator and/or Medical Monitor.
The Role of Auditory Feedback in Guiding Upper Extremity Movements

Stroke is one of the leading causes of disability, with an estimated prevalence of 50,000 cases per year in Canada. Less than half of stroke patients regain use of their arm and hand. There is currently no intervention regime that is the gold standard, despite the variety of therapeutic techniques used to treat the upper extremity post-stroke. The use of external feedback to improve motor learning is a technique that has been less studied but shows promise. Therefore, the purpose of this proof of principle study it to test whether different auditory feedback frequencies can facilitate reaching ability in people with stroke. In addition brain scans will be collected that will enable us to determine how stroke severity may impact on one's ability to improve with this technique.

We hypothesize that patients who receive less feedback (50% alternate) will have enhanced learning relative to the patients who receive more feedback (100%).


Eligibility Criteria:
Inclusion Criteria:

* Unilateral first time MCA ischemic stroke
* Stroke patients should have some movement of shoulder/elbow (no movement of hand - e.g. hand, fingers - is OK)
* \> 2 months post
* between 30-85 years

Exclusion Criteria:

* prior stroke
* severe comprehension (or cognitive) deficit that compromises informed consent or understanding of instructions
* contraindications to MRI (e.g. claustrophobia, metal implants)
* neurodegenerative or psychiatric disease
* apraxia
* auditory deficits that would impair testing
* prior musculoskeletal injury to back or upper extremity (including shoulder subluxation from stroke)
* skin conditions that would preclude taping of goniometers
Induction of Labour for LGA fœtus in Women Without Insulin-treated Diabetes.

A french study published in 2015 (DAME) showed a decrease of shoulder dystocia and an increase of spontaneous vaginal delivery when the non insulin-treated diabetes patients with large-for-date fetus were induced.

This new protocole was introduced in Montpellier University Hospital delivery room.

The aim of this study is to evaluate the protocole in Montpellier hospital and to compare our results with the DAME results.

Currently, large for date fœtus need an induction of labour just if the mother is an insulin diabetic.

The DAME's protocol included the large for date feotus witch have a estimate weight \>3500g at 36 GA, \>3700g at 37 GA, \>3900g at 38 GA.

Eligibility Criteria:
Inclusion criteria:

Age \>18 years old Single pregnancy Cephalic presentation no contraindications to planned vaginal delivery no fœtal pathology

Large-for-date foetus (estimated weight \> 95%) :

* Clinically suspeted or estilated weight \>90% at the 3 trimester ultrasound
* Estimated fœtal weight :

\> 3500g at 36 GA \> 3700g at 37 GA \> 3900g at 38 GA

Exclusion criteria:

Age \<18 yeaurs old contraindications to vaginal delivery insulin-trated diabetics or imbalance diabetics. neonatal trauma or shoulder dystocia, severe urinary or faecal incontinence.
Bethaherpesviruses in Children Who Are Immune Suppressed

Unexplained fever in children with cancer is a common occurrence, often requiring hospital admission for evaluation and treatment with intravenous antibiotics. While empiric use of intravenous antibiotics is the norm in this population, between 48-70% of febrile and neutropenic episodes remain without an identifiable source. An understudied area is the potential role of betaherpesvirus infections in such febrile episodes. These viruses are significant pathogens in patients who become immunocompromised in conjunction with organ transplantation or acquired immune deficiency syndrome (AIDS). It is possible that they are similarly pathogenic in children who become immunocompromised due to cancer chemotherapy.

Thus, we will investigate the association between the betaherpesviruses and fever in children with cancer. The betaherpesviruses include cytomegalovirus (CMV), human herpesvirus 6A (HHV-6A), human herpesvirus 6B (HHV-6B), and human herpesvirus 7 (HHV-7). These viruses are grouped based on shared biological and genetic properties. Each is commonly acquired in childhood, persists in the human host, and can reactivate. Reactivation occurs intermittently throughout life in healthy individuals and is seldom associated with disease. Immune suppression is associated with a higher likelihood of reactivation and clinical disease. Latency of these viruses involves highly regulated processes that result in the viruses evading destruction and persisting within the host. Should balance be disrupted, as with cancer and anticancer therapy altering the normal host state, the environment may become favorable for betaherpesvirus reactivation, leading to disease and further alterations of the immune system.


Eligibility Criteria:
Inclusion Criteria:

1. Newly diagnosed with cancer (leukemia, lymphoma, or solid tumor)
2. Undergoing solid organ pre-transplantation evaluation
3. Age birth to 21 years

Exclusion Criteria:

1. Unwilling to participate in the study
2. Unwilling to have specimens stored for future research
3. Clinical conditions preclude the required amount of blood to be drawn for the study
4. Patient has malignancy that has relapsed
5. Patient is not a primary transplant candidate (ie. has already had a solid organ transplant) -
Anti-stigma Intervention for Chinese American Older Adults

Approximately 50 participants will be enrolled and screened to achieve 45 eligible patients with mood/anxiety disorders to complete a 10 weekly anti-stigma group intervention (ASGI) in addition to several self-report internalized stigma and psychiatric measures.This study will examine changes in internalized stigma and psychiatric symptoms pre- and post-ASGI with 3 months post-intervention follow-up.


Eligibility Criteria:
Inclusion Criteria:

* Self-reported Chinese heritage;
* 55 years or older
* Mandarin and/or Cantonese speaking and ability to read and/or comprehend spoken Chinese language.
* Currently receiving treatment from a mental health provider at Gouverneur Medical Center Asian Bicultural Clinic (GMC ABC) and willing to continue mental health care through the study.
* Willing to provide release for communication between primary mental health care provider and study staff throughout the study.
* Documented by mental health provider after consent for release of information as having mood and anxiety disorder diagnosis in the past year;
* A willingness to participate in the ASGI with stated availability;
* Able and willing to provide informed consent.

Exclusion Criteria:

* Lifetime psychosis, neurocognitive, or significant neurological disorders;
* Current manic episode;
* Past 6 months of alcohol/substance use disorder;
* Serious safety concerns of suicide or homicide.
EFFECTS OF VESTIBULAR REHABILITATION THERAPY (VRT) ON BALANCE, SPEED AND AGILITY IN POST-CONCUSSION FOOTBALL PLAYERS

Traumatic brain injury (TBI) is one and utmost rampant attained neurological conditions which can happen in young adults. Vestibular Rehabilitation Therapy can help them improve their balance, speed and agility.

Total 40 sample size out of which were divided into control and experimental group. Concussed football athletes with age ranging 15-25 year, those participating actively in the sports were included in the study in the region of Kyber Pukhtoonkhwa Peshawar.

Eligibility Criteria:
Inclusion Criteria:

Active Male football player. Age between 15-25 years. Known cases of concussion were included in the study. Those patients complaining mild vertigo \& participating in sports

Exclusion Criteria:

Concussion other than sports. History of metabolic diseases. History of recent fractures.
A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296.

A study conducted on healthy volunteers to determine the safety, tolerability and affect on the human body by experimental drug GSK557296.


Eligibility Criteria:
Inclusion Criteria:

* Healthy males who are 18 to 45 years of age
* Body mass index between 19 and 30 with a body weight greater than 110 pounds and deemed healthy by a physician
* Non-smokers

Exclusion Criteria:

* Alcohol consumption averaging more than 7 drinks per week
* Positive for Hepatitis C antibody, Hepatitis B antigen or HIV
* Any use of prescription drugs or non prescription drugs
Efficacy of Continous Regional Anesthesia Using m. Erector Spinae Catheter After VATS Procedures

Investigators will analyze the efficacy of continuous regional anesthesia through a catheter under erector spinae muscle in a prospective, randomized, double blind, placebo-controlled study. Investigators will include 50 adults, predicted for elective lung surgery with video-assisted thoracic surgery (VATS) technique. Patients will be randomly assigned to group A or B.

Investigators will insert a catheter under the erector spinae muscle (ESC) at the T4 level of the operated side under ultrasound guidance. All patients will receive an initial bolus of 20ml levobupivacaine 0,5% through the catheter. Group A will receive a continuous infusion 5ml/h of ropivacaine 0,2% and intermittent boluses of the same local anesthetic 15ml/4h through the ESC. Group B will receive a continuous infusion of 0,9% saline in the same doses. All patients will have a PCA pump with piritramide 1mg/ml to cover the pain. All patients will receive regular doses of paracetamol and metamizole as part of multimodal analgesia.

Investigators will compare pain, assessed with the VAS scale in resting and coughing and piritramide usage in both groups. Investigators will compare the incentive spirometry results at 24 and 48 hours postoperatively and observe for possible late complications.


Eligibility Criteria:
Inclusion Criteria:

* Signed written informed consent
* ASA I-III
* Elective video-assisted thoracic surgery with 3 ports technique
* No contraindications for regional anesthesia

Exclusion Criteria:

* Allergy to local anesthetic
* Pregnancy, breastfeeding
* BMI\>35
* Inflammation in the area of ES catheter insertion
* Inability to use the PCA pump
Quality of Recovery From Mastectomy With and Without PECS Blocks

This is a prospective observational study. Investigators want to understand post-operative recovery for patients undergoing mastectomy at NorthShore University HealthSystem. Some of these patients receive PECS blocks with Liposomal Bupivacaine and some do not receive a block. Investigators want to know whether patients who receive a block have better post operative recovery and pain control than patients who do not receive one. Investigators also want to understand whether PECS blocks with Liposomal Bupivacaine improves quality of recovery at 72 hours post operatively.

Investigators plan to approach and consent 800 patients undergoing mastectomy, 400 with PECS blocks and 400 without. Investigators will assess their quality of recovery using the QoR 15 survey at 72 hours post operatively. In addition, investigators will also record VAS scores immediately postoperatively and at 24, 48, and 72 hours postoperatively. The study team will also calculate the total morphine equivalents (MMEs) required for each patient after 72 hours.

Eligibility Criteria:
Inclusion Criteria:

Must be female Must be \>18 years old and \< 90 years old Must be able to consent in English or Spanish May or may not have breast cancer (prophylactic mastectomy) Must be undergoing unilateral or bilateral mastectomy of any type May choose to proceed with or without breast reconstruction

Exclusion Criteria:

* Allergy to all narcotic or local anesthetic medications Intake of any chronic opioids or pain medications preoperatively for a chronic condition or chronic use.

Subjects who received PECS blocks but whose block failed or is deemed not effective by an anesthesia provider as indicated by postoperative evaluation exam.

Vulnerable subjects (children, prisoners, pregnant women)
An Observational Clinical Study to Evaluate COVID-19 Symptoms in "Long Hauler" Patients Who Participated in K031-120 or K032-120

This observational clinical study aims to evaluate the presence of symptoms of COVID-19 infection in patients who participated in K031-120 or K032-120 ("long hauler").


Eligibility Criteria:
Inclusion Criteria:

* Have consented to participate over the telephone
* Have been randomized in either the K031-120 or K032-120 study

Exclusion Criteria:

* Have withdrawn consent from K031-120 or K032-120
Adjuvant Use Of Colchicine With The Standard Therapy In Moderate And Severe Corona Virus Disease-19 Infection

The study included 2 arms Colchicine group: Colchicine + standard therapy of COVID-19 Control group: Standard therapy of COVID-19

This study will be a randomized controlled trial with 2 arms study trial 1:1 allocation. The sample size was calculated and we need a total of 160 patients (80 Colchicine add on group and 80 controls)

Eligibility Criteria:
Inclusion Criteria:

* 1. Patients with age above 18 years and of any gender 2. Definite diagnosis of COVID-19 according to the WHO classification criteria 3. Patients symptomatic for no more than three days for mild-moderate cases, no more than two days after being severe cases 4. Understands and agrees to comply with planned study procedures.

Exclusion Criteria:

1. Patients refuse to enrol in the study
2. Patients with hypersensitivity to colchicine
3. Patients with chronic diseases: Renal failure with eGFR\<30 ml/min; chronic liver disease with hepatic failure (AST/ALT \> 3x normal).; decompensated heart failure, long QT syndrome (QTc \>450 msec.), and uncontrolled arrhythmia; inflammatory bowel disease, chronic diarrhea or malabsorption; pre-existent progressive neuromuscular disease, and Metastatic cancer
4. Pregnancy and breast feeding
5. Medications: immunosuppressive chemotherapy; regular use of digoxin, amiodarone, verapamil or protease inhibitors.
Effect on Pain and Comfort Associated With Fistula Puncture

Purpose This study was carried out as the design of the targeted design in terms of targeting and comfort in the patient with hemodialysis.

Material and Methods: It was successfully tested both in the control team of a hospital at the point of sale in Turkey and with experience. By block randomization method to randomize. Data were collected with "Patient identification formula", "Visual Analog Scale (VAS)" and "Hemodialysis Comfort Scale". Independent sample t-test was used in the analysis of the data, analysis of variance in repeated measurements and Cohen'd was used to calculate the size.

It is appropriate to suggest a non-pharmacological rather clinical rather than a literature-free method, al. Also, due to the fact that the duration of anesthetic effect will expire from the dialysis treatment used (Subramanian et al., 2012).

Participant's care continues for inappropriate pain management. This quality standard is one of the criteria of a standard rather than a preference for a simple, reliable and inexpensive non-pharmacological choice.

As far as investigators know, there are very few studies investigating the effect of a patient's choice of music on pain following insertion of a needle into a fistula in hemodialysis patients. More focused on non-pharmacological types such as pharmacological and aromatherapy. Therefore, the aim of this study was to examine the effect of the type of music chosen by hemodialysis patients on pain and comfort associated with fistula puncture.

Eligibility Criteria:
Inclusion Criteria:

* be volunteering,
* 18 years or older,
* receiving hemodialysis treatment for at least 6 months
* not any hearing problem.

Exclusion Criteria:

* have hearing problem
* not be volunteering.